EGFR and interstitial lung disease: Similarly, a phase Ib clinical trial of concurrent durvalumab plus osimertinib in EGFR-mutant lung cancer reported ILD in 38 % (13/34) of patients, bringing an early halt to the enrollment of patients in this arm [87].